Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash from Operations (2016 - 2025)

Regenxbio has reported Cash from Operations over the past 12 years, most recently at 52290000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 52290000.0 for Q4 2025, down 65.35% from a year ago — trailing twelve months through Dec 2025 was 123963000.0 (up 28.4% YoY), and the annual figure for FY2025 was 123963000.0, up 28.4%.
  • Cash from Operations for Q4 2025 was 52290000.0 at Regenxbio, up from 55960000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for RGNX hit a ceiling of 341497000.0 in Q4 2021 and a floor of 80918000.0 in Q1 2023.
  • Median Cash from Operations over the past 5 years was 46409500.0 (2023), compared with a mean of 25205400.0.
  • Biggest five-year swings in Cash from Operations: surged 765.25% in 2021 and later tumbled 111.53% in 2022.
  • Regenxbio's Cash from Operations stood at 341497000.0 in 2021, then tumbled by 111.53% to 39372000.0 in 2022, then fell by 3.53% to 40760000.0 in 2023, then rose by 22.41% to 31624000.0 in 2024, then tumbled by 65.35% to 52290000.0 in 2025.
  • The last three reported values for Cash from Operations were 52290000.0 (Q4 2025), 55960000.0 (Q3 2025), and 49342000.0 (Q2 2025) per Business Quant data.